PRLog - Jan. 23, 2013 - 6th & 7th February 2013: this two day intensive programme will showcase how leading Pharma companies are beginning to combat traders and attempt to prevent counterfeit medicines entering the market. Through a series of case studies attendees will learn how trading can affect future R&D pipelines in drug development. Parallel trade has a unique and important legal issues attached to it you will hear from specialist pharmaceutical lawyers explaining issues with intellectual property and specific aspects of repackaging.
Key topics for 2013 include:
· Effects of Parallel Trade on Patient Safety – How do patients benefit from parallel trade, quality issues and safety concerns.
· Supply Chain Protection –the impact on parallel trade on pharmaceutical manufacturers
· Key panel discussion with members including parallel traders, pharma executives and legal experts who can break down exactly where trading is.
· Working with the Falsified Medicines Directive –how the ruling is affecting counterfeiters and benefits to patient safety.
The event will also feature two post-conference workshops on Parallel Trade in Life Sciences and Parallel Trade Management Strategies.
For the full conference programme and further information please visit:
Alternatively contact Fateja Begum: +44(0)
About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-
We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. We hold events in over 30 major cities throughout the world including London, Paris and Singapore and to date have welcomed over 200,000 participants from 80 countries.
A full programme and further information can be found at